⌕
Relay Therapeutics · RLAY · Nasdaq
Tenet 43 · Weak
Compare
$17.27−4.53%At closeTenet 43 · Weak
$17.27−0.82 (−4.53%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Relay Therapeutics (RLAY) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Jun 30, 2026. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 261 filers, Jun 30, 2026
# 13F FUNDS
261
13F VALUE
$4.7B
249.8M shares
Not reported in the company's filings for this period.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 28, 2026Rahmer PeterSee remarksDisposed · Open-market sale753$18.62↗
Oct 28, 2026Bergstrom Donald APresident, R&DDisposed · Open-market sale2,252$18.62↗
Oct 28, 2026Catinazzo ThomasChief Financial OfficerDisposed · Open-market sale1,469$18.62↗
Oct 7, 2026Patel SanjivPresident and CEODisposed · Open-market sale48,199$18.10↗
Oct 6, 2026Catinazzo ThomasChief Financial OfficerDisposed · Open-market sale17,511$18.58↗
Oct 6, 2026Catinazzo ThomasChief Financial OfficerDisposed · Open-market sale206$19.26↗
Sep 8, 2026Bergstrom Donald APresident, R&DDisposed · Open-market sale8,530$18.97↗
Sep 8, 2026Catinazzo ThomasChief Financial OfficerDisposed · Open-market sale17,717$18.94↗
Sep 8, 2026Patel SanjivPresident and CEODisposed · Open-market sale48,199$18.94↗
Aug 26, 2026Rahmer PeterSee remarksDisposed · Open-market sale4,508$20.03↗
Aug 25, 2026SVF Pauling (Cayman) Ltd10% ownerDisposed · Open-market sale6,000,000$19.40↗
Aug 17, 2026Patel SanjivPresident and CEODisposed · Open-market sale48,199$20.33↗
Aug 14, 2026Catinazzo ThomasChief Financial OfficerDisposed · Open-market sale17,717$19.74↗
Jul 28, 2026Catinazzo ThomasChief Financial OfficerDisposed · Open-market sale1,459$18.61↗
Jul 28, 2026Rahmer PeterSee remarksDisposed · Open-market sale748$18.61↗
Jul 28, 2026Bergstrom Donald APresident, R&DDisposed · Open-market sale2,237$18.61↗
Jul 7, 2026Patel SanjivPresident and CEODisposed · Open-market sale48,199$19.58↗
Jul 6, 2026Bergstrom Donald APresident, R&DDisposed · Open-market sale8,660$18.71↗
Jul 6, 2026Catinazzo ThomasChief Financial OfficerDisposed · Open-market sale17,717$18.69↗
Jun 30, 2026Patel SanjivPresident and CEOAcquired · Grant / award3,056$6.95↗

* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold Relay Therapeutics?

Relay Therapeutics was held by 261 13F filers as of Jun 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.